2024-09-28 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis:

**1.  Performance Comparison:**

* **Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing life-changing medicines for serious diseases.
* **Cumulative Returns:**
    * **REGN:** 98.32%
    * **VOO (S&P 500):** 134.22%
* **Deviation:**
    * **Absolute:** -35.9%
    * **Relative:** 38.88% (Currently at 38.88% of the range between the minimum and maximum deviation observed historically) 

**2.  Recent Price Movement:**

* **Closing Price:** $1039.96
* **5-day Moving Average:** $1067.33
* **20-day Moving Average:** $1133.14
* **60-day Moving Average:** $1116.89

**3.  Technical Indicators:**

* **RSI:** 30.97 (Suggests the stock is currently oversold)
* **PPO:** -1.43 (Indicates potential bearish momentum)
* **Delta_Previous_Relative_Divergence:** -28.51 (Short-term downtrend)
* **Expected Return:** 0.0% (Represents the maximum expected return over the next 5 years based on current investment) 

**4.  Recent Earnings and Outlook:**

| Date        | EPS      | Revenue     |
|-------------|----------|-------------|
| 2024-08-01 | 13.25    | 3.55 B$      |
| 2024-05-02 | 6.7      | 3.15 B$      |
| 2023-11-02 | 9.48     | 3.36 B$      |
| 2023-08-03 | 9.05     | 3.16 B$      |
| 2024-08-01 | 9.05     | 3.16 B$      | 

* **Most Recent Earnings:** The most recent earnings report (2024-08-01) showed EPS of 13.25, exceeding analyst expectations.  Revenue also exceeded forecasts, indicating continued strong performance. 

**5.  News and Recent Issues:**

* **Recent Market Outlook:** 
    * **FINBOLD:** Reports suggest Regeneron Pharmaceuticals Inc. has a "Strong Buy" rating. The company's strong earnings and promising pipeline of new drugs are fueling optimism.
* **Analyst Opinions:** 
    * **Performance Highlights:** Regeneron has consistently outperformed the industry average in recent years, with its focus on treatments for severe diseases driving growth.
    * **Key Factors:**  Analysts are particularly bullish on the company's ongoing clinical trials for its new ophthalmology treatments and the recent approval of a new Eylea formulation.
* **Key Issues:** 
    * **Competition:** The biotechnology sector is highly competitive, with several other companies developing similar treatments. 
    * **Regulatory Landscape:** The approval process for new drugs can be lengthy and expensive.

**6.  Comprehensive Analysis:**

Regeneron Pharmaceuticals Inc. is a high-growth company with a strong track record of innovation. While its recent performance has been below the S&P 500, it is still a compelling investment option for investors seeking exposure to the biotechnology sector. The company's strong earnings, promising pipeline, and positive analyst sentiment suggest continued growth potential. However, investors should be aware of the competitive landscape and the inherent risks associated with the biotechnology industry.

**7.  Technical Summary:**

* **Overall:** REGN currently appears oversold, with RSI below 30.
* **Price Movement:** The stock has experienced a recent downtrend, but it is still above its key moving averages.
* **Recent Earnings:** The most recent earnings report was positive, suggesting continued strong performance.
* **Analyst Opinions:** The majority of analysts are bullish on REGN, citing its strong pipeline and growth potential.

**Disclaimer:** This analysis is for informational purposes only and does not constitute investment advice. 
